Sobica

# Sobica ## Overview - **Classification**: Macrolide-like Broad-Spectrum Antibiotic - **Mechanism**: Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Treatment of moderate to severe bacterial pneumonia. 2. **Complicated Skin and Soft Tissue Infections (cSSTI)** - Including cellulitis, abscesses, and wound infections. 3. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - For susceptible organisms. ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP) / Complicated Skin and Soft Tissue Infections (cSSTI)** - **Dose**: **500 mg** - **Frequency**: Every **12 hours** (q12h) - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7-14 days, depending on infection severity and clinical response. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - **Dose**: **250 mg** - **Frequency**: Every **12 hours** (q12h) - **Route**: Oral (PO) - **Duration**: 5-7 days. ### Dose Adjustments - **Renal Impairment**: - CrCl **30-60 mL/min**: No initial adjustment. Monitor for adverse effects. - CrCl **<30 mL/min**: Reduce dose by **50%**. Max **250 mg** q12h. - **Hepatic Impairment**: - Mild to Moderate: No adjustment, but use with caution. - Severe: **Contraindicated**. - **Elderly Patients**: No specific dose adjustment, but consider age-related decline in renal function. Start at lower end of dosing range. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Generally **not recommended** due to potential for bilirubin displacement and QTc prolongation. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use only if no suitable alternatives exist for life-threatening infections, with extreme caution and continuous cardiac monitoring. ### Infants (1-12 months) - **Dose**: **10 mg/kg/dose** - **Frequency**: Every **12 hours** (q12h) - **Maximum**: **250 mg/dose** - **Special Notes**: Consider oral suspension for accurate dosing. ### Children (1-12 years) - **Dose**: **15 mg/kg/dose** - **Frequency**: Every **12 hours** (q12h) - **Maximum**: **500 mg/dose** (or **1000 mg/day**) - **Special Notes**: Oral tablets or suspension may be used depending on age and ability to swallow. ### Adolescents (13-18 years) - **Dose**: Follow **Adult Dosing** recommendations. - **Maximum**: **1000 mg/day** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Sobica or any macrolide antibiotic. - **Absolute**: History of QTc prolongation or ventricular arrhythmias (including torsades de pointes). - **Absolute**: Severe hepatic impairment (Child-Pugh Class C). - **Absolute**: Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Abdominal pain - **Common (1-10%)**: Vomiting, Headache, Dizziness, Rash - **Serious but Rare**: QTc prolongation, Torsades de pointes, Hepatotoxicity, *Clostridioides difficile*-associated diarrhea (CDAD). ### Key Drug Interactions - **QTc Prolonging Drugs**: Increased risk of fatal arrhythmias. Avoid co-administration. - **CYP3A4 Substrates**: Sobica is a moderate CYP3A4 inhibitor; may increase levels of simvastatin, tacrolimus, cyclosporine. Monitor and adjust doses. - **Warfarin**: Enhanced anticoagulant effect, increased bleeding risk. Monitor INR closely. - **Antacids (containing aluminum/magnesium)**: May decrease Sobica absorption. Administer Sobica 2 hours before or 4 hours after antacids. ## Monitoring & Follow-up - **Before Treatment**: - Baseline **ECG** (if QTc risk factors). - Baseline **LFTs** (ALT, AST, ALP, bilirubin). - Electrolytes (K+, Mg2+). - **During Treatment**: - Monitor **LFTs** (weekly for prolonged therapy or if signs of hepatotoxicity). - Monitor **ECG** and electrolytes (K+, Mg2+) if QTc risk factors or symptoms develop. - Assess for resolution of infection symptoms. - **Clinical Signs**: Watch for persistent nausea/vomiting, severe diarrhea, jaundice, dark urine, or palpitations/syncope. ## Clinical Pearls - 💡 **Take with food** to minimize GI upset and improve tolerability. - 💡 **Complete the full course** of therapy, even if feeling better, to prevent resistance. - 💡 **Counsel patients** on signs of QTc prolongation (dizziness, fainting) and hepatotoxicity (yellow skin/eyes, dark urine). - 💡 **Report severe diarrhea** that persists after treatment, as it may indicate CDAD. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.